Search clinical trials for: CELLECTRA®2000 EP Device

Total 639 results

MedImmune LLC

Completed

Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

Head and Neck Cancer | Human Papilloma Virus

United States
Geneos Therapeutics

Active, not recruiting

GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC

HCC

United States, New Zealand
Inovio Pharmaceuticals

Completed

Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

Prostate Cancer

United States
Inovio Pharmaceuticals
Coalition for Epidemic Preparedness Innovations

Completed

Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers

Lassa Fever

United States
Inovio Pharmaceuticals
Coalition for Epidemic Preparedness Innovations

Completed

Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers

Coronavirus Infection

United States
Inovio Pharmaceuticals

Withdrawn

Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers

Coronavirus Infection
Inovio Pharmaceuticals

Completed

INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)

Respiratory Papillomatosis

United States
Inovio Pharmaceuticals
Coalition for Epidemic Preparedness Innovations

Completed

Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana

Lassa Fever

Ghana
Washington University School of Medicine
The Foundation for Barnes-Jewish Hospital; Geneos Therapeutics

Active, not recruiting

Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Glioblastoma

United States
GeneOne Life Science, Inc.
International Vaccine Institute; Inovio Pharmaceuticals

Completed

Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers

Healthy

Korea, Republic of
Inovio Pharmaceuticals
Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.

Terminated

Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Coronavirus Infection | COVID-19 Disease

United States, Mexico, Colombia
University of Pennsylvania
Inovio Pharmaceuticals

Completed

A Study of INO-A002 in Healthy Dengue Virus-naive Adults

Healthy Volunteers

United States
Steven Deeks
National Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaborators

Completed

Therapeutic Vaccination in Treated HIV Disease

HIV-1-infection

United States
University of Pennsylvania
Inovio Pharmaceuticals

Recruiting

INO 5401 Vaccination in BRCA1/2 Mutation Carriers

BRCA1/2 Mutation

United States
Mayo Clinic
Qatar National Research Fund

Completed

Prediction of Cardiovascular Events in Vulnerable Patients Following Acute Coronary Syndrome

Acute Coronary Syndrome

United States
Inovio Pharmaceuticals
Coalition for Epidemic Preparedness Innovations

Completed

Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers

Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

Lebanon, Jordan, Kenya
GlaxoSmithKline

Completed

Study on the Immunogenicity and Tolerability of Influsplit SSW® 2005/2006 in Children Aged 6 - 13 Years

Influenza

Germany
Sunovion Respiratory Development Inc.

Completed

Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study

Chronic Obstructive Pulmonary Disease

United States, United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Influenza Virus Vaccines in Children and Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® Vaccine

Influenza

United States
Pablo Tebas
AstraZeneca; Inovio Pharmaceuticals; The Wistar Institute

Recruiting

dMAbs for Prevention of COVID-19

Healthy Volunteers

United States
GlaxoSmithKline

Completed

Reacto & Immunogenicity of TF Formulation of Influsplit SSW® 2002/03 v/s Std Formulation of Influsplit SSW® 2002/03

Influenza

Germany
Sanofi

Completed

Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects

Influenza | Myxovirus Infection | Orthomyxoviruses

United States
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of Fluarix™ (Influsplit SSW®) 2007/2008 in People 18 Years Old or Above

Influenza

Germany
Seqirus

Completed

A Study to Assess the Immunogenicity and Safety of CSL's 2009 / 2010 Formulation of Enzira® Vaccine in Healthy Volunteers

Influenza

United Kingdom
Sanofi

Completed

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States
Jazz Pharmaceuticals

Completed

A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy (SPRAY)

Pain | Cancer | Palliative Care

United Kingdom
GlaxoSmithKline

Completed

Immuno & Reacto of TF Trivalent Influenza Split Vaccine 2003/04 or of Std Formulation Influsplit SSW®/Fluarix™ 2003/04

Influenza

Germany
Inovio Pharmaceuticals

Active, not recruiting

INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

Urothelial Carcinoma

United States
Beijing Jishuitan Hospital

Unknown

Radial Extracorporeal Shock Wave Therapy on Chronic Low Back Pain: a Prospective Controlled Study

Low Back Pain

China
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

B-cell Immunity to Influenza (SLVP017)- Year 1, 2009

Influenza

United States
International Vaccine Institute
Inovio Pharmaceuticals; Coalition for Epidemic Preparedness Innovations

Completed

Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19

Coronavirus Infection | SARS-CoV 2

Korea, Republic of
Kepler University Hospital

Completed

Warmed, Humidified Carbon Dioxide Insufflation vs Standard Carbon Dioxide in Laparoscopic Cholecystectomy

Cholecystolithiasis

Austria
Washington University School of Medicine
National Institute on Deafness and Other Communication Disorders (NIDCD)

Completed

Collaborative Tinnitus Research at Washington University (CTRWU)

Subjective Tinnitus

United States
Inovio Pharmaceuticals

Completed

Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

Human Papillomavirus (HPV) | Vulvar Dysplasia | Vulvar Intraepithelial Neoplasia (VIN) | Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) | VIN2 | VIN3 | Pre-cancerous Lesions of the Vulva

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA (HVTN119)

HIV Infections

United States
Queen's University

Terminated

Cardiac Resynchronization Therapy, Dyspnea and Exercise Tolerance in Patients With Congestive Heart Failure (CHF)

Congestive Heart Failure

Canada
Children's Hospital of Orange County
NeurOptics Inc.

Recruiting

Utility of Pupillary Metrics in Diagnosis and Management of Concussion in Children

Brain Injuries, Traumatic | Brain Concussion | Reflex, Pupillary | Post-Concussion Syndrome

United States
Sanofi Pasteur, a Sanofi Company

Completed

Phase IV Trial to Collect Safety Data and Sera for Immunogenicity Testing in Healthy Children Given Fluzone® Vaccine

Influenza

United States
Biotronik SE & Co. KG

Recruiting

Post-market Clinical Follow-up Data Collection From Procedures With BIOTRONIK EP Products (BIO|COLLECT-EP)

Cardiac Arrhythmia

Germany
Medtronic Neurovascular Clinical Affairs

Completed

SOLITAIRE™ FR With the Intention For Thrombectomy (SWIFT) Study (SWIFT)

Ischemic Stroke

United States
PathMaker Neurosystems Inc.
National Institute of Neurological Disorders and Stroke (NINDS); Spaulding...

Recruiting

Study Evaluating MyoRegulator® Treatment in Post-Stroke Upper Limb Spasticity (RECOVER)

Stroke | Muscle Spasticity

United States
Medical College of Wisconsin

Withdrawn

Preoperative Self-managed Respiratory Therapy for Reduction of Postoperative Pulmonary Complications (PRESMART)

Postoperative Respiratory Complication

United States
Derming SRL

Completed

Aesthetic Performance of an Intradermal Injection Treatment for Face Photoaging: Interstitial or Cushion Technique in Comparison to Bolus Technique at Five Points (Half - Face Method Within Subjects)

Face Photoaging

Italy
Cefaly Technology

Completed

A Phase III Trial of e-TNS for the Acute Treatment of Migraine (TEAM)

Migraine

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Safety and Immunogenicity of Fluzone® in Healthy Children

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age

Influenza

United States
Alejandro Berenstein

Recruiting

PHIL® Embolic System Pediatric IDE

Intracranial Arteriovenous Malformations | Arterio-venous Fistula

United States
David A. Talan
Light AI, Inc.

Completed

Pilot Study of Strepic® Device for the Diagnosis of Group A Streptococcal Pharyngitis

Group A Streptococcal Infection

United States

Search clinical trials for: CELLECTRA®2000 EP Device

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations